Tripeptide-29 vs Leuprolide
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Tripeptide-29Sexual Health & Libido
Leuprolide- Summary
- Tripeptide-29 is a pro-collagen cosmetic peptide composed of proline, hydroxyproline, and glycine — the core repeating unit of collagen. Applied topically, it signals dermal fibroblasts that collagen degradation has occurred, triggering compensatory new collagen synthesis.
- Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
- Half-Life
- Not applicable (topical)
- ~3 hours (SC/IM), but depot formulations last 1–12 months
- Admin Route
- Topical
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 0.01-0.1% in formulation
- 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
- Frequency
- Once or twice daily
- Per depot schedule
- Key Benefits
- Stimulates fibroblast collagen synthesis via damage-signal mechanism
- Reduces fine lines and improves skin smoothness
- Supports dermal matrix integrity
- Naturally bioidentical to collagen fragment sequences
- Well-tolerated in all skin types
- Synergistic with copper peptides and retinoids
- Medical: reduces testosterone in prostate cancer
- Medical: suppresses estrogen in endometriosis and uterine fibroids
- Medical: delays precocious puberty
- Research: testosterone rebound effect after short course
- Transgender care: hormone suppression in adolescents
- Research: hormonal re-sensitization protocols
- Side Effects
- Excellent tolerability profile
- No documented significant adverse effects at cosmetic concentrations
- Rare sensitivity reactions in individuals with peptide allergies
- Hot flashes (with testosterone suppression)
- Decreased libido and erectile dysfunction
- Initial testosterone flare (first 1–2 weeks)
- Bone density loss with long-term use
- +3 more
- Stacks With
- —
- —